Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Gloucester Pharmaceuticals
Woman and Man Max 99 years
Gloucester Pharmaceuticals Inc
Update Il y a 4 ans
A single agent Phase II study of depsipeptide (FK228) in the treatment of Cutaneous T-cell lymphoma
To confirm the efficacy of FK228, depsipeptide, as reported in the Phase I and early Phase II studies, in patients with CTCL who are no longer controlled on skin-directed therapy and who have had at l...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Gloucester Pharmaceuticals Inc
Update Il y a 4 ans
An exploratory Phase II, multicenter, open-label trial evaluating the activity and tolerability of of FK228 in androgen independent metastatic prostate cancer patients with a rising PSA
The primary objective of this trial is to evaluate the activity of FK228 in patients with metastatic prostate cancer who have developed a rising PSA while undergoing hormonal therapy. Activity will b...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Gloucester Pharmaceuticals
Update Il y a 4 ans
Gloucester GPI-06-0002 : Essai de phase 2 évaluant l’efficacité et la tolérance d’un traitement par romidepsin chez des patients ayant un lymphome. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
A phase II, multicenter, open-label trial evaluating the activity and tolerability of romidepsin (depsipeptide, FK228) in progressive or relapsed peripheral T-cell lymphoma following prior systemic th...
Country
France
organs
Leucémies aiguës
Specialty
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Gloucester Pharmaceuticals Inc
Update Il y a 4 ans
A MULTICENTER, OPEN-LABEL CONTINUATION TRIAL EVALUATING THE TOLERABILITY AND ACTIVITY OF DEPSIPEPTIDE (FK228) IN PATIENTS THAT HAVE COMPLETED A PRIOR CLINICAL STUDY WITH DEPSIPEPTIDE
The primary objective of this trial is to evaluate the safety and tolerability of extended treatment with depsipeptide in patients who have at least demonstrated stable disease on a prior Gloucester-s...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Gloucester Pharmaceuticals Inc
Update Il y a 4 ans
A PHASE II, MULTICENTER, OPEN-LABEL TRIAL EVALUATING THE ACTIVITY AND TOLERABILITY OF ROMIDEPSIN (DEPSIPEPTIDE, FK228) IN PROGRESSIVE OR RELAPSED PERIPHERAL T-CELL LYMPHOMA FOLLOWING PRIOR SYSTEMIC THERAPY
The primary objective of this trial is to evaluate the activity of romidepsin in patients with progressive or relapsed PTCL following prior systemic therapy. The primary efficacy parameter is the rat...
Country
None
organs
None
Specialty
None
unknown
More information